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Background. Food safety authorities discovered that wild boar meat products contaminated with Trichinella
spiralis had entered the food chain in Germany in March 2013. Public health authorities issued guidelines for health
professionals including post-exposure prophylaxis (PEP) using mebendazole and advised the public to seek medical
advice if exposed. Our objective was to identify factors associated with the development of trichinellosis and to eval-
uate post exposure prophylaxis.
Methods. Persons who reported to local public health departments as exposed were interviewed concerning ex-
posure, symptoms, and medication. Serum samples were tested by an in-house Trichinella-specific enzyme-linked
innunosorbent assay. Cases were defined as persons presenting with myalgia and/or periorbital edema and Trichi-
nella-specific immunoglobulin M and immunoglobulin G antibodies after exposure to implicated products.
Results. Of 101 persons interviewed, 71 were exposed and serologically tested. Antibodies were detected in 21/71
(30%) and 14/71 (20%)met the case definition. Attack rates were positively correlated to the amount of implicated prod-
uct consumed. Among n = 37 persons who received anthelmintics as PEP, 6 persons developed trichinellosis. These
cases exclusively occurred among persons starting PEP 6 days or later post-exposure. Exposure to implicated products
and delaying PEP were also significantly associated with developing trichinellosis (P < .01) in a multivariable analysis.
Conclusions. Concerted efforts by food safety and public health authorities lead to timely outbreak control and fa-
cilitated the provision of early PEP. PEP appears to be effective in preventing trichinellosis when given early, preferably
within 6 days. We therefore recommend initiating PEP without delay in similar settings and encourage public health
professionals to fast-track this intervention.
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Human trichinellosis occurs through consumption of
raw or inadequately processed meat or meat products
containing larvae of the parasitic nematodes of the
genus Trichinella. The course of human infection can
be divided into 2 phases: The first or intestinal phase
lasts approximately 1 to 2 weeks and is associated with
diarrhea and abdominal pain caused by the reproduc-
tion of adult nematodes in the intestinal mucosa. The
second or muscular phase occurs approximately 1
week post-infection when new born larvae penetrate
the mucosa and migrate throughout the body until
they reach the cells of the striated skeletal muscles
[1]. This phase is characterized by fever, periorbital
edema, and myalgia [2]. Possible complications are
myocarditis, thromboembolic disease, and encephalitis.
Chronic myalgia can persist. In cases following a high
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infectious dose, lethality is estimated to be as high as 5% despite
treatment [3].
Pork represents the most important source of human infec-
tion worldwide, but horse or game meat also plays a significant
role [4]. In the majority of countries in the Americas and
Europe including Germany, trichinellosis cases are rare due to
controlled housing conditions in commercial swine herds and
systematic inspection of meat intended for human consumption
[3–5]. Outbreaks however are not uncommon in connection
with game meat, especially wild boar [6–9].
Anthelmintics such as mebendazole and albendazole are the
principal drugs used for the treatment of trichinellosis [2].
Upon diagnosis, treatment should be initiated as soon as possi-
ble to eliminate the parasite in the gastrointestinal tract and thus
reduce the generation of the newborn larvae and their migration
into striated muscle tissue [10]. Data from animal models sug-
gest that the development of muscle stage larvae can be prevent-
ed if anthelmintics are administered within the first few days of
exposure [11–13]. Apart from a small case series [14], studies
evaluating the effectiveness of post-exposure prophylaxis
(PEP) in humans and in an outbreak setting are not available.
Outbreak Setting
On 27 March 2013, the National Reference Laboratory for Trich-
inella (NRL-T) at the Federal Institute for Risk Assessment dis-
covered during routine molecular typing that the carcass of a
Trichinella infected boar had accidentally been declared fit for
human consumption. Eight kilograms of the muscle tissue of
this carcass had already been used in the production of 1050
cured raw sausages (“knacker sausage”), and further 30–35 kg
were sold as fresh meat intended to be cooked. The fresh meat
was on sale on 23, 26, and 27 March at the store of a game-
handling establishment and at mobile retail food establish-
ments in 16 cities and towns in the federal states of Saxony and
Brandenburg (Figure 1). The sausages, intended to be eaten raw,
were on sale on 26 and 27 March only. On 28 March 2013, the
Robert-Koch-Institute as national public health authority was in-
formed about the incident and invited to support the outbreak
investigation of the local public health and food safety authorities.
The objective of this investigation was to assess the extent of
the outbreak, to identify factors that are associated with the
development of trichinellosis, and to evaluate effectiveness of
anthelmintic medication administered as post-exposure pro-
phylaxis in an outbreak situation.
METHODS
Public Health and Food Safety Action
Immediate measures included the identification and tracing of
implicated meat products, the withdrawal from the market of
any unsold stock, as well as informing primary care physicians,
internal medicine specialists, and emergency departments in the
area about the expected outbreak and the possibility of PEP. A
press release was issued on 28 March 2013 advising consumers
to return or dispose of the implicated products and to seek med-
ical attention as soon as possible if exposed. After ad hoc consul-
tations with clinical infection specialists, recommendations on
PEP for asymptomatic persons and treatment were issued as
shown in Table 1 [15]. A dedicated telephone hotline was imple-
mented for the public by the local health department (LHD) and
ran over the long Easter holiday weekend until 5 April 2013.
Study Design and Epidemiological Investigation
We conducted a prospective cohort study among persons with
self-reported exposure to the implicated products using investi-
gator administered questionnaires and serological investiga-
tions. A case was defined as a person with Trichinella-specific
immunoglobulin M (IgM) and/or immunoglobulin G (IgG)
and self-reported symptoms of myalgia and/or periorbital
edema following consumption of the implicated product.
Participants were recruited among persons contacting LHDs
for information or serological testing following the press release
of 28 March 2013. All persons who reported having eaten prod-
ucts from the affected batch were invited to participate in a tele-
phone or face-to-face interview with an epidemiologist or public
health official and offered Trichinella-specific laboratory diagnos-
tics. Our questionnaire included items on demographics, date
Figure 1. Locations (“X”) within the federal states of Brandenburg and
Saxony where the implicated products were on sale between March 23
and 27. Inset shows the location within Germany and neighboring coun-
tries. Outbreak of trichinellosis, Germany, 2013.
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and place of purchase, date of exposure, food preparation and
amount eaten, leftover products in the household, clinical symp-
toms, and contact to the healthcare system including recommen-
dation of and compliance to PEP. Blood specimens were
collected at the LHD or, if preferred, at a physician’s office of
the exposed persons’ choice at the earliest 45 days after exposure
and sent to the NRL-T for analysis. In case of inconclusive sero-
logical results, blood sampling and serological testing were re-
peated 10 weeks after exposure. Participants were followed up
at least once if initial contact had occurred within the first 6
weeks post-exposure to allow for reporting of late symptoms
and detection of late seroconversion.
Ethical Considerations
In accordance with article 25, section 1, of the German Infec-
tion Protection Act of 2001, a formal ethical review process
and approval was not required for this investigation of an ongo-
ing outbreak. Data protection and medical ethics standards
were adhered to as regulated by law. Informed consent was ob-
tained by all participants or, if applicable, their legal guardians.
Laboratory Testing
Serological investigations were conducted using an enzyme-
linked immunosorbent assay (ELISA) based on the excretory-
secretory antigen [16] and implemented for the examination
of human sera [17]. The sensitivity/specificity of the ELISA
are 94%/85% and 89%/96% for the detection of human anti-
Trichinella-IgM and -IgG, respectively. All positive and incon-
clusive ELISA results were confirmed by Western blot adapted
for examination of human sera [18].
Product samples collected at the meat processing establish-
ment as well as leftover products from private households
were analyzed at the NRL-T for Trichinella according to regu-
lation EC (No.) 2075/2005 [19]. The number of larvae per gram
(lpg) was calculated for each sample. Identification of the larvae
at the species level was performed by means of multiplex poly-
merase chain reaction (PCR) [20].
Statistical Analysis
Attack rates (AR) and exposure-specific relative risks (RR) and
95% confidence intervals (CI) were calculated. Rank sum or
t-tests were used with continuous variables; Cuzick test was used
for trend with data across ordered groups. Prevalence ratios
were calculated to investigate the predictive value of self-reported
symptoms for seroconversion. To evaluate PEP failure, we ana-
lyzed a subset of persons who received anthelmintic medi-
cations as PEP. Multivariable regression analyses with case
status as the dependent variable (using forward elimination of
variables with a cut-off P-value of 0.2 and adjusted for age and
sex) were performed using a fitted generalized linear model
(“binreg”) in Stata version 13 (Stata Corp., Texas).
RESULTS
A total of 101 persons or their legal guardians agreed to be in-
terviewed of whom 84 had eaten the implicated products. Fol-
low-up serological results and information on individual PEP
regimens was available for 71 exposed persons who thus met
the inclusion criteria for this analysis.
Laboratory Investigation
Serological investigations indicated a recent Trichinella infec-
tion in 21 of 71 (30%) exposed persons, of which 17 (81%)
were positive for both anti-Trichinella-IgM and –IgG (con-
firmed by Western blot) and 4 (19%) showed a seroconversion
for anti-Trichinella-IgM between 6 and 10 weeks post-exposure.
Among 9 persons, with an initially inconclusive ELISA result
≥45 days after exposure, 5 (56%) had developed anti-Trichinella-
IgM and/or -IgG, 2 (22%) were negative by ELISA and further
2 persons (22%) were confirmed negative by Western blot upon
retesting 10 weeks after exposure.
The larval burden (larvae per gram, lpg) in the diaphragm
muscle of the Trichinella infected wild boar was 60 lpg. The lar-
val burden in 10 sausages (weighing 100 grams each) collected
at the company ranged from 0.3 to 0.7 lpg (median: 0.5 lpg;
standard deviation: 0.13). Three sausages collected from 3 dif-
ferent households contained Trichinella larvae with a larval bur-
den ranging from 1.1 to 1.3 lpg. The larvae were identified as
Table 1. Recommendations on Diagnostics and Post-Exposure
Prophylaxis and Treatment Issued to Health Care Professionals
During the Outbreak of Trichinellosis, Germany, 2013 [15]
Scenario Recommendation
Asymptomatic person
presenting within 7 d
of exposure
Mebendazole 5 mg/kg body weight,
twice daily for 5 d. Contraindication:
Children younger than 2 years and
pregnant women (Pyrantel may be
considered).
Asymptomatic person
presenting within 8 to
30 d of exposure
Conduct laboratory testing. If eosinophilia
(>500/µL), elevated creatine kinase
(CK) levels or Trichinella-specific
antibodies are detected, treatment
should be discussed with a specialized
center (serology may be negative
initially). If all tests are negative: no
further measures.
Reassess if symptoms develop.
Asymptomatic person
presenting more than
30 d post exposure
No further diagnostics.




any point of time
Conduct laboratory testing (eosinophilia,
elevated creatine kinase (CK) levels,
and Trichinella-specific antibodies.
If negative: repeat laboratory diagnostics
after a few days.
If positive in initial or follow-up test, a
specialized center should be contacted.
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Trichinella spiralis by multiplex PCR. No larvae were detected
in the remaining 3 sausages from an additional household.
Epidemiological Investigation
Exposed persons were between 3 and 87 years old (mean: 52
years) and lived in 4 different federal states (Saxony, Branden-
burg, Bavaria, Lower-Saxony). Thirty-five (49%) persons were
female. Two persons were hospitalized during follow-up; no
deaths occurred. Exposure ranged from less than 1 up to 6 sau-
sages (n = 65) or from 1 to 4 or more portions of wild boar roast
(n = 5); only one person reported having eaten both sausage and
wild boar roast. The median exposure was 1 sausage or 1 por-
tion of wild boar roast. The cured raw sausages were typically
consumed on the day of purchase (78%) or the following day
(12%) (mean 0.44 days, range 0–8 days). Cooking, frying, or
other means of heating above 71°C/160F of the sausages before
consumption were not reported.
A total of 44/71 (62%) persons (all adults) had received an-
thelmintic medication: 42 (95%) persons took mebendazole
(Vermox forte) and 2 (5%) took albendazole. Medication was
taken for a median time of 6 days (interquartile range: 3.5–9
days). One person discontinued due to adverse effects after
the first dose and 1 person took mebendazole for as long as
21 days. Twenty-nine persons (66%) took 2 doses per day, 11
(25%) spread their medication into 3 or more daily doses,
and 4 (9%) took medication as single daily dose.
Risk Factors for the Development of Trichinellosis and
Effectiveness of PEP
Among persons who had eaten sausages and could specify the
exact amount, 14/65 fulfilled the case definition (AR = 21.5%).
Seven persons seroconverted without developing myalgia or
periorbital edema. No seroconversions occurred among persons
who only ate wild boar roast (n = 5). The AR among those who
had eaten less than 1 sausage (1/21 [5%]) increased more than
4-fold among those who had eaten 1 or 2 sausages (10/44
[AR = 22.7%], RR = 4.76) and again almost 3-fold if more
than 2 sausages (3/5 [AR = 60%], RR = 12.6) were eaten, dem-
onstrating a strong dose-response relationship (Cuzick test for
trend, P < .006). The AR among persons who received anthel-
mintic medication as post-exposure prophylaxis (6/37,
AR = 16.2%) was lower than among those who did not (8/26,
AR = 30.8%); the difference, however, was not statistically sig-
nificant (P > .17). No association was found between case status
and age group, sex, or date and place of purchase.
To further evaluate PEP failure, we analyzed the subset of
persons who received mebendazole or albendazole as PEP
(n = 37), that is, before developing clinical symptoms consistent
with trichinellosis and/or Trichinella-specific antibodies (ex-
cluding persons who received anthelmintics as treatment). A
correlation between the number of days since exposure until
the first dose of PEP medication and PEP failure was evident:
No cases of trichinellosis were observed among those who
had received the first dose of PEP within 6 days post-exposure
(n = 21, AR = 0%). PEP failure was observed in 4/12 (33.3%)
persons starting PEP within 7–10 days and in 2/4 (50%) persons
starting within 11–17 days, respectively (Figure 2, Cuzick test
for trend: P < .002). In univariable analyses, we did not find dif-
ferences between cases and noncases in terms of the number of
daily doses or the number of consecutive days on anthelmintics.
In the final multivariable model (which included all 37 persons
who received anthelmintics as PEP) adjusting for age and sex,
the factors associated with trichinellosis according to the case
definition were the number of sausages consumed (RR = 2.75,
95% CI, 1.52–4.97), the delay (in days) between exposure
and start of anthelmintic medication (RR = 1.63, 95% CI,
Figure 2. Patient outcome by post-exposure prophylaxis (PEP) delay following consumption of implicated sausages, outbreak of trichinellosis, Germany,
2013 (n = 37).
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1.23–2.16), and the number of consecutive days on PEP
(RR = 0.77, 95% CI, .66–.90).
Predictive Value of Self-reported Symptoms With Regard to
Seroconversion
Diarrhea, headache, and myalgia were the most frequently re-
ported symptoms among all exposed persons (Table 2). A dif-
ference in frequency among persons who did and did not
seroconvert was most evident with regard to periorbital edema,
fever ≥38°C, and myalgia as indicated by high prevalence ratios.
Symptoms that typically occur soon after infection (in the gas-
trointestinal phase of the disease) such as diarrhea and abdom-
inal pain were reported almost as often by persons who did not
seroconvert as by those who did seroconvert and thus had a low
predictive value for seroconversion.
DISCUSSION
We report on a large outbreak of trichinellosis in Germany
associated with wild boar meat and products thereof involving
at least 14 cases of trichinellosis and possibly several hundreds
of exposed persons. We found that among those who received
anthelmintic drugs as PEP, cases of trichinellosis exclusively oc-
curred among persons who started PEP later than 6 days post-
exposure. The occurrence of (early) gastrointestinal symptoms
following exposure carried no predictive value for later serocon-
version in our study.
This outbreak confirms that game and meat from animals
raised outside of controlled housing conditions continues to pose
a risk to consumers [21], especially in cultures with affinity to eat
raw meat preparations and raw sausages. Recent outbreaks due
to consumption of such foodstuffs occurred in Poland [22],
Romania [23], Lithuania [24], Italy [8], and in the United States
in Illinois [7] and Iowa [6]. The present outbreak underlines that
meat from a single infected wild boar carcass can contaminate a
large batch of meat products and thus put hundreds of people
at risk of disease if it is not heated before consumption. Roasting
the infected wild boar meat was apparently sufficient to pre-
vent Trichinella infections. Diligent food safety inspections of
potentially Trichinella-contaminated meat are implemented in
Germany [19] and would have normally prevented this outbreak.
Additional quality assurance measures have been implemented
to assure reliable results from meat inspection.
The contaminated sausages were typically eaten on the day of
purchase or the day after. The viability and infectivity of larvae
was thus likely not reduced due to the passing of time as demon-
strated from previous studies [25].Congruent with this finding, we
found a strong dose relationship between the number of sausages
consumed and the development of trichinellosis. Seroconversion
after infection with Trichinella spp. usually occurs between the
2nd and 5th week and is inversely correlated with the infective
dose [26]. Most persons who were seropositive 6 weeks after ex-
posure showed a low initial titer for anti-Trichinella-IgM and
-IgG. This can be explained by a prolonged seroconversion due
to the relatively low number of larvae (30–130) per sausage.
This study is to our knowledge the first to prospectively eval-
uate the effectiveness of post-exposure prophylaxis in an out-
break of trichinellosis. In the multivariable analysis, delaying
administration of PEP was an independent risk factor in addi-
tion to the number of sausages eaten and a shorter duration of
Table 2. Prevalence of Symptoms Among Study Participants (Total and by Serological Outcome) and Prevalence Ratios Following
Consumption of Implicated Meat Products, Outbreak of Trichinellosis, Germany, 2013
Symptom









Myalgia and/or periorbital edema 26.5% 66.7% 8.5% 7.8 [2.93–20.97]
Myalgia 19.1% 47.6% 6.4% 7.5 [2.29–24.36]
Periorbital edema 13.0% 38.1% 2.1% 18.3 [2.44–137.10]
Headache 23.2% 47.6% 12.5% 3.8 [1.59–9.12]
Fever >38°C 13.0% 33.3% 4.2% 8.0 [1.81–35.34]
Chills 13.0% 28.6% 6.3% 4.6 [1.26–16.57]
Diarrhea 26.1% 28.6% 25.0% 1.1 [.50–2.63]
Abdominal pain 17.4% 23.8% 14.6% 1.6 [.58–4.56]
Cough 8.7% 14.3% 6.3% 2.3 [.51–10.41]
Conjunctivitis 7.2% 9.5% 6.3% 1.5 [.27–8.46]
Cardiac symptoms (NOS) 1.4% 4.8% 0.0% ∞
Abbreviations: CI, confidence interval; NOS, not otherwise specified.
a The prevalence ratio is equivalent to the positive likelihood ratio (LR+) in diagnostic testing. Here it denotes how much likelier a positive serological test is in an
exposed person when the respective symptom is present compared to when it is not.
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treatment. The distribution of cases and noncases by time of
PEP administration as shown in Figure 2 reveals a sharp cut-
off with cases exclusively occurring in the group that received
PEP 6 days post exposure or later. Although there is controversy
concerning the effectiveness of mebendazole during the muscu-
lar phase of trichinellosis [27, 28], our data thus suggests that if
taken within the first 6 days of exposure the development of
clinical trichinellosis in humans can effectively be prevented.
Supporting evidence comes from several animal studies [11–
13] and a case series involving 4 persons exposed to a high
dose of Trichinella larvae treated with mebendazole within 48
hours of exposure [14]. It is assumed, that such early application
of anthelmintics kills larvae and adult forms in the gut before
new larvae are produced and migrate to other parts of the
body. Mebendazole may be particularly suitable for the use in
PEP as (a) it is poorly absorbed in the gastrointestinal tract,
leading to a high concentration in the lumen [29], and (b) it
was shown to be highly effective against intestinal stages of
the parasite [14]. Albendazole, on the other hand, may be
more useful should the larvae have already migrated and have
become established in the muscles [30]. Randomized clinical
trials comparing different treatments are scarce, and the small
number of persons in our study that were administered alben-
dazole does not allow us to recommend one drug over the other.
We would like to emphasize that the results of this study do
not suggest anthelmintics should be withheld if a patient presents
more than a week after exposure. In trichinellosis, the severity of
extraintestinal disease is proportional to the number of larvae
produced by adult worms in the small intestine. Thus, it is imper-
ative to rid the gut of adult parasites even if the patient presents
late and with only mild gastrointestinal symptoms [31].
A post-exposure prophylaxis recommendation carries the
risk of administering drugs to and causing adverse effects in
persons that are not infected and would not have needed treat-
ment. We thus analyzed whether early symptoms could be used
as a predictor for seroconversion on which a decision to admin-
ister PEP could be based. We found that periorbital edema and
myalgia are distinctive clinical signs of trichinellosis, indicated
by high prevalence ratios between persons that did and did not
seroconvert, yet they only occur after larvae have already dis-
seminated from the gastrointestinal tract. Fever and chills
were predictive as well, yet these symptoms are unspecific.
Early symptoms like diarrhea and abdominal pain linked to in-
vasion of the intestinal mucosa by the parasite had little or no
predictive power for later outcome in our outbreak setting.
CONCLUSIONS AND RECOMMENDATIONS
Mebendazole can apparently prevent the development of clinical
trichinellosis if administered within the first 6 days of alimenta-
ry exposure. We therefore recommend that PEP is offered to all
persons with exposure to meat containing viable Trichinella lar-
vae in a similar outbreak setting. Due to the unspecific nature of
the early symptoms of trichinellosis, the decision to recommend
or withhold PEP should not be based on symptoms but on po-
tential exposure. The key measures to prevent human trichinel-
losis, however, remain the prevention of Trichinella infection in
livestock and the systematic sampling and examination of po-
tentially infected meat intended for human consumption.
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